Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kyowa Pres. Eyes Excursion into Authorized Generic Territory
June 26, 2014
- X-Linked Hypophosphatemia Treatment Improves Phosphate Metabolism in PI/II Study: Kyowa Kirin
June 26, 2014
- BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field
June 26, 2014
- Nihon Chouzai Reaches Price Settlements with All Wholesalers; Expects to Avoid Reductions in Basic Dispensing Fees
June 25, 2014
- SGLT-2 Inhibitors Vigorously Increase in Anterio’s “Mind Share” Ranking in May
June 25, 2014
- Sanofi-Brand Generics of Diovan, Zometa Hit Shelves in Japan
June 24, 2014
- Diovan, Zometa Authorized Generics Now Available in Japan
June 24, 2014
- Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
- Prevenar 13 Approved for Use in Elderly: Pfizer Japan
June 24, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- Blopress AGs Scheduled for Release in Mid-September: ASKA
June 20, 2014
- Kyowa Kirin Starts PI Study of Aβ Peptide Antibody for Alzheimer's Disease in Europe
June 20, 2014
- Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
- Takeda Launches Zacras Combination Tablets
June 20, 2014
- DSP Now Renamed “Sumitomo Dainippon Pharma” in English
June 19, 2014
- Serious ADRs Reported in Xeljanz EPPV Include Heart Failure, Pneumonia: Prof.
June 19, 2014
- Novartis Begins Global Filings for PV Treatment Ruxolitinib following Positive PIII Results
June 19, 2014
- Ono Calls Off License Pact with German Peer Merck for ONO-4641
June 19, 2014
- Japan Vaccine President and Chairman Swap Posts
June 19, 2014
- Fycompa Meets Primary Endpoints in Patients with PGTC Seizures in PIII Study: Eisai
June 19, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…